<DOC>
	<DOCNO>NCT01697670</DOCNO>
	<brief_summary>Objectives : Primary : The primary study objective determine clinical response assess Mayo score low dose PDT patient moderate severe active distal UC . Secondary : The secondary study objective assess effect inflammation safety tolerability low dose PDT patient moderate severe active distal UC . This multicenter , open phase II study enroll maximum 20 eligible patient moderate severe active distal UC . The first 10 eligible patient , first cohort , receive PDT 10 Joule per square centimetre ( J/cm2 ) dose intensity . If clinical response observe first 7 eligible patient , study stop due lack efficacy . If least 1 clinical response observe first 7 patient , first cohort complete total 10 eligible patient - Trial medicinal product</brief_summary>
	<brief_title>Photodynamic Therapy Ulcerative Colitis</brief_title>
	<detailed_description>Subsequently , follow algorithm apply : - &gt; 3 clinical responder SD8 , another 10 patient , second cohort , expose PDT dose intensity - &lt; 3 clinical responder , without adverse proctosigmoidoscopic observation SD8 , second cohort , expose next high PDT dose intensity 15 J/cm2 - &lt; 3 clinical responder , adverse proctosigmoidoscopic observation SD8 , second cohort , expose next low PDT dose intensity 5 J/cm2 - The safety continuously evaluate throughout study . The screen phase consist 1 week ( SD-7 - SD0 ) , treatment phase 4 week ( SD1-SD29 ) , follow-up evaluation phase 4 week ( SD30-SD57 ) , equate overall duration 9 week per patient . It foresee least 3 participate investigational site complete accrual first cohort 3 month , second cohort , appropriate additional 3 month . In case low recruitment , extra site ask participation . Hence study duration study initiation last patient complete study 8 month reach primary analysis study . The follow-up analysis complete 3 month later . Stopping rule : Requirement prohibit medication surgical procedure Requirement increase dose permit medication SAE think attributable PDT Grade III IV toxicity ( CTC v3.0 ) think attributable PDT Patients request withdraw Lost follow-up Investigational Medicinal Device : All patient drink 50 ml orange juice contain 15 mg/kg 5-aminolevulinic acid ( 5-ALA ) . After 3 hour , lesion illuminate red light 635 nm use cylindrical light diffuser ( Model RD , Medlight SA ) white diffuse inflatable balloon catheter ( model CDB OEB , Medlight SA ) fluence rate 65.5 mW/cm2 153 second result total light dose 10 J/cm2 . The first cohort treat ligh</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Inclusion criterion : ? An establish documented diagnosis UC Moderate severe active distal UC Mayo score 610 proctosigmoidoscopy score 2 Distal UC assess proctosigmoidoscopy , i.e . major lesion sigmoid colon rectum lesion extend splenic flexure Glucocorticosteroids , aminosalicylates certain immunosuppressant permit specific condition define concomitant medication section Exclusion criterion : ? Have participate investigational study receive experimental therapeutic procedure consider interfere study 4 week precede SD1 UC complication ( e.g . stricture , pouchitis ) Use follow immunosuppressant 12 week precede SD1 : cyclosporine , thalidomide derivative , mycophenolate mofetil Use antibiotics 2 week precede SD1 Use non steroidal antiinflammatory drug ( NSAIDs ) 2 week precede SD1 Use antitumor necrosis factor ( TNF ) biologics 8 week precede SD1 Porphyria , erythropoietic protoporphyria hypersensitivity porphyrins Uncontrolled medical condition , require surgical pharmacological treatment Inadequate bone marrow reserve : White blood cell ( WBC ) &lt; 3.5x109/L , neutrophil &lt; 1.0x109/L , thrombocytes &lt; 100x109/L , haemoglobin ( Hb ) &lt; 8.5 g/dL coagulation abnormality Inadequate liver function : total bilirubin &gt; 1.5 x upper limit normal value aspartate aminotransferase ( ASAT ) , alanine aminotransferase ( ALAT ) , alkaline phosphatase &gt; 2.5 x upper limit normal Have inadequate renal function , define serum creatinine &gt; 250 Âµmol/L Serious concomitant disease ( e.g . severe cardiovascular disease , chronic obstructive pulmonary disease ) History cancer &lt; 5 year History alcohol and/or drug abuse Pregnant lactate woman fertile woman unless surgically sterile use one highly effective method + barrier method till end study ( SD29 ) Female patient must pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>